2021-04-28 |
2021-04-26 |
B
Purchase
|
Meyers Michael L.
SVP, Chief Medical Officer
Officer
|
500
+3.3%
15.46
7,730
USD
|
500
+3.3%
|
15.46
|
7,730
USD
|
|
2021-04-22 |
2021-04-22 |
B
Purchase
|
Podlesak Dennis
Non-Executive Director
|
13,967
+47.6%
14.11
197,077
USD
|
13,967
+47.6%
|
14.11
|
197,077
USD
|
|
2021-03-03 |
2021-03-01 |
PS
Planned sale
|
Egros Fabrice
Non-Executive Director
|
74
-0.5%
24.31
1,799
USD
|
74
-0.5%
|
24.31
|
1,799
USD
|
|
2021-03-03 |
2021-03-01 |
PS
Planned sale
|
Egros Fabrice
Non-Executive Director
|
10,167
-38.7%
24.31
247,182
USD
|
10,167
-38.7%
|
24.31
|
247,182
USD
|
|
2021-02-10 |
2021-02-08 |
PS
Planned sale
|
Morrison Briggs
Chief Executive Officer
Executive Director
|
35,156
-42.1%
20.55
722,403
USD
|
35,156
-42.1%
|
20.55
|
722,403
USD
|
|
2021-02-03 |
2021-02-01 |
PS
Planned sale
|
Metzger Michael A
President and COO
Executive Director
|
15,000
-45.9%
20.19
302,799
USD
|
15,000
-45.9%
|
20.19
|
302,799
USD
|
|
2020-12-03 |
2020-12-01 |
PS
Planned sale
|
Metzger Michael A
President and COO
Executive Director
|
15,000
-45.9%
22.97
344,513
USD
|
15,000
-45.9%
|
22.97
|
344,513
USD
|
|
2020-11-25 |
2020-11-23 |
S
Sale
|
Ordentlich Peter
Chief Scientific Officer
Officer
|
16,334
-100.0%
22.89
373,924
USD
|
16,334
-100.0%
|
22.89
|
373,924
USD
|
|
2020-11-25 |
2020-11-23 |
S
Sale
|
Ordentlich Peter
Chief Scientific Officer
Officer
|
7,954
-32.7%
23.58
187,594
USD
|
7,954
-32.7%
|
23.58
|
187,594
USD
|
|
2020-11-25 |
2020-11-23 |
S
Sale
|
Ordentlich Peter
Chief Scientific Officer
Officer
|
5,684
-19.0%
23.33
132,603
USD
|
5,684
-19.0%
|
23.33
|
132,603
USD
|
|
2020-11-12 |
2020-11-10 |
S
Sale
|
Morrison Briggs
Chief Executive Officer
Executive Director
|
17,466
-27.3%
20.06
350,312
USD
|
17,466
-27.3%
|
20.06
|
350,312
USD
|
|
2020-11-12 |
2020-11-09 |
S
Sale
|
Morrison Briggs
Chief Executive Officer
Executive Director
|
62,938
-57.5%
20.04
1,261,265
USD
|
62,938
-57.5%
|
20.04
|
1,261,265
USD
|
|
2020-11-06 |
2020-11-04 |
PS
Planned sale
|
Metzger Michael A
President and COO
Executive Director
|
100,000
-85.0%
20.31
2,031,410
USD
|
100,000
-85.0%
|
20.31
|
2,031,410
USD
|
|
2020-02-05 |
2020-02-04 |
B
Purchase
|
Morrison Briggs
Chief Executive Officer
|
12,500
+39.8%
8.00
100,000
USD
|
12,500
+39.8%
|
8.00
|
100,000
USD
|
|
2019-10-11 |
2019-10-10 |
B
Purchase
|
Morrison Briggs
Chief Executive Officer
|
11,000
+53.9%
5.40
59,400
USD
|
11,000
+53.9%
|
5.40
|
59,400
USD
|
|
2019-05-13 |
2019-05-13 |
B
Purchase
|
Morrison Briggs
Chief Executive Officer
|
7,200
+54.5%
7.29
52,517
USD
|
7,200
+54.5%
|
7.29
|
52,517
USD
|
|
2019-05-13 |
2019-05-09 |
B
Purchase
|
Morrison Briggs
Chief Executive Officer
|
13,200
+inf%
7.56
99,726
USD
|
13,200
+inf%
|
7.56
|
99,726
USD
|
|
2019-03-22 |
2019-03-21 |
B
Purchase
|
Meyers Michael L.
SVP, Chief Medical Officer
|
104
+1.5%
4.87
506
USD
|
104
+1.5%
|
4.87
|
506
USD
|
|
2019-03-22 |
2019-03-21 |
B
Purchase
|
Meyers Michael L.
SVP, Chief Medical Officer
|
1,000
+16.3%
4.93
4,930
USD
|
1,000
+16.3%
|
4.93
|
4,930
USD
|
|
2018-11-07 |
2018-10-30 |
PP
Planned purchase
|
Meyers Michael L.
SVP, Chief Medical Officer
|
200
+9.1%
4.79
958
USD
|
200
+9.1%
|
4.79
|
958
USD
|
|
2018-04-03 |
2018-04-03 |
PS
Planned sale
|
Ordentlich Peter
Chief Scientific Officer
|
7,500
-100.0%
15.00
112,500
USD
|
7,500
-100.0%
|
15.00
|
112,500
USD
|
|
2017-05-19 |
2017-05-17 |
PS
Planned sale
|
Ordentlich Peter
Chief Scientific Officer
|
5,000
-100.0%
15.00
75,000
USD
|
5,000
-100.0%
|
15.00
|
75,000
USD
|
|
2016-03-08 |
2016-03-08 |
B
Purchase
|
ROYSTON IVOR
Non-Executive Director
|
150,000
+25.0%
12.00
1,800,000
USD
|
150,000
+25.0%
|
12.00
|
1,800,000
USD
|
|